The contract announced today covers initial activities in developing a controlled release formulation of an undisclosed compound using our proprietary drug delivery technology PolyActive®. If the evaluation is successful, the project may progress into a full development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or send an e-mail to Investor Relations at IR[at]octoplus[dot]nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics.
The clinically most advanced product incorporating our technology is Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has completed Phase IIb clinical studies with superior clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.
OctoPlus N.V.
Zernikedreef 12, 2333 CL, Leiden
Phone: +31 (71) 5244044, www.octoplus.nl
Sector: Biotechnology - Therapeutics
Description: OctoPlus is a drug product development services company that is globally renowned as a center of excellence in formulation development, drug delivery and GMP manufacturing of injectables. OctoPlus offers: -1- Drug formulation development services (including analytical development and manufacturing process development), -2- cGMP manufacturing, and -3- Controlled release technologies.